X

Pfizer inc (PFE) Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer inc (NYSE: PFE) FY 2026 Other Release

Newsdesk: